Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have received an average rating of “Moderate Buy” from the twenty-six brokerages that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $628.78.

TMO has been the subject of a number of recent analyst reports. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research note on Friday. HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 1st. Finally, Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Deutsche Bank reaffirmed a favorable growth outlook. The bank said Thermo Fisher’s building blocks for growth through 2028 remain “fundamentally sound,” supporting confidence in the company’s long-term earnings trajectory. Thermo Fisher Scientific’s Building Blocks to 2028 Growth Fundamentally Sound Deutsche Bank Says
• Positive Sentiment: Thermo Fisher launched a new Gibco CHO-K1 Catalog Panel. The cGMP-ready, chemically defined media portfolio is designed to help biologics and biosimilar developers improve cell growth, protein yields and manufacturing flexibility. The launch could strengthen Thermo Fisher’s position in biologics-supporting products. Thermo Fisher Scientific Rolls Out New Media Panel for Biologics Development
• Positive Sentiment: Industry forecasts point to expanding demand across Thermo Fisher’s markets. Cell isolation, cell culture media and reusable bioreactors are expected to grow as biologics, cell therapies, personalized medicine and vaccine production expand. These forecasts suggest favorable long-term demand for Thermo Fisher’s life-science tools and consumables. Cell Isolation Cell Separation Market Forecasts Growth
• Positive Sentiment: Thermo Fisher is participating in Biodesix’s MRD monitoring programs. The collaboration with Bio-Rad and Biodesix involves circulating tumor DNA testing after cancer treatment, providing potential exposure to growth in molecular diagnostics and oncology monitoring. Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
• Neutral Sentiment: A review of a decade-long investment in Thermo Fisher highlights the stock’s strong long-term returns, but it is backward-looking and offers limited new information for near-term trading. Here’s How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today
• Negative Sentiment: Valuation may be limiting upside. With shares trading near their 52-week high and at a premium earnings multiple, investors may be locking in gains while awaiting additional evidence that new product launches can justify the elevated valuation. Thermo Fisher Scientific Launches Gibco CHO K1 Panel on a Fair Value Question

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 over the last quarter. Insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in shares of Thermo Fisher Scientific in the second quarter worth $15,501,867,000. Corient Private Wealth LP purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $382,547,000. Norges Bank purchased a new position in Thermo Fisher Scientific in the 4th quarter worth $3,072,744,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $1,974,561,000. Finally, Bank of America Corp DE purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at about $1,952,930,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $674.54 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a 12 month low of $435.27 and a 12 month high of $682.98. The stock has a market cap of $249.41 billion, a PE ratio of 36.29, a P/E/G ratio of 2.84 and a beta of 0.85. The company has a 50-day moving average price of $606.05 and a 200 day moving average price of $528.43.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.